Ventyx Biosciences Inc

Ventyx Biosciences — Technical Presentation (November 2023)

14 slides from Ventyx Biosciences's technical presentation, Nov 6, 2023

  1. Slide 1: VTX958 Phase 2 Plaque Psoriasis Results

    VTX958 Phase 2 Plaque Psoriasis Results November 6, 2023 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Su

  3. Slide 3: Introduction

    Introduction Raju Mohan, Ph.D. Founder and Chief Executive Officer

  4. Slide 4: Phase 2 Plaque Psoriasis Trial Design Overview

    Phase 2 Plaque Psoriasis Trial Trial Design Overview Key eligibility criteria: Adult participants with moderate to severe plaque psoriasis as defined by PASI score ≥ 12, sPGA score ≥ 3 and BSA ≥ 10%. History of plaque psoriasis for ≥ 6 months and deemed eligible by investigator for phototherapy or s

  5. Slide 5: Baseline Demographics and Disease Characteristics

    Baseline Demographics and Disease Characteristics Placebo (N=43) VTX958 50 mg BID (N=45) VTX958 300 mg QD (N=44) VTX958 225 mg BID (N=45) VTX958 300 mg BID (N=43) Age, years, mean (SD) 44.2 (13.1)​ 45.7 (13.1)​ 46.2 (12.7)​ 45.0 (14.5)​ 43.5 (13.8)​ Male, n (%) 28 (65.1%)​ 28 (62.2%)​ 30 (68.2%)​ 32

  6. Slide 6: Participant Disposition

    LTFU: Lost to follow up; BID: twice daily; QD: once daily. Source: Ventyx data on file. Participant Disposition

  7. Slide 7: Primary and Secondary Endpoints at Week 16

    Primary and Secondary Endpoints at Week 16 Proportion of Participants Achieving PASI 75, 90, and 100 *p<0.05; **p<0.005; ***p<0.001. P values from Cochran-Mantel-Haenszel test, using prior biologic treatment as a stratification factor. PASI: Psoriasis Area and Severity Index; BID: twice daily; QD: o

  8. Slide 8: Safety Summary: Summary of Adverse Events

    Safety Summary Summary of Adverse Events through Week 16 Treatment Emergent Adverse Events (TEAE) Placebo (N=43) VTX958 50 mg BID (N=45) VTX958 300 mg QD (N=44) VTX958 225 mg BID (N=45) VTX958 300 mg BID (N=43) Subject with any adverse event, n (%) 18 (42%) 17 (38%) 20 (46%) 28 (62%) 25 (58%) Advers

  9. Slide 9: Safety Summary: Treatment Emergent Laboratory Shifts with CTCAE Grade ≥3

    Safety Summary Treatment Emergent Laboratory Shifts with CTCAE Grade ≥3 CTCAE: Common Terminology Criteria for Adverse Event (version 5.0); INR: International Normalized Ratio. Source: Ventyx data on file. Treatment Emergent Laboratory Shifts with CTCAE Grade ≥3 Placebo (N=43) VTX958 50 mg BID (N=45

  10. Slide 10: VTX958 Program Status and Next Steps

    VTX958 Program Status and Next Steps Crohn’s Trial to Proceed to Interim Analysis in Q1 2024 SES-CD: Simple Endoscopic Score for Crohn’s Disease; CDAI: Crohn’s Disease Activity Index Baseline Week 12 Screening Period 12-Week Treatment Period 225 mg BID Placebo 300 mg BID 1:1:1 R Patients with Modera

  11. Slide 11: Extended-Release Formulation Update

    Extended-Release Formulation Update Once-Daily Formulation Achieved with Target Release Profile Target profile achieved with extended-release (ER) formulation: QD dose with ER formulation approximates BID exposures observed with immediate release (IR) tablets IC90 coverage achieved with 375 mg QD do

  12. Slide 12: Broad Pipeline of Small Molecule Candidates

    Target Program Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestones TYK2 VTX958 Phase 2 CD interim analysis Q1 2024 S1P1R VTX002 Phase 2 UC OLE update Q1 2024 Initiate Phase 3 trial 2024 NLRP3 Peripheral VTX2735 Phase 2 CAPS data update Q1 2024 NLRP3 CNS-penetrant VTX3232 Phase 1 data upd

  13. Slide 13: Conclusions

    Conclusions Ventyx to Provide Portfolio Updates in Q1 2024 Phase 2 plaque psoriasis trial achieved primary and all secondary endpoints Trial results in PsO fall short of threshold for advancement into Phase 3 Phase 2 trials in plaque psoriasis and psoriatic arthritis to be discontinued Ongoing Phase

  14. Slide 14: Q&A Session

    Q&A Session Ventyx Management Team

Ventyx Biosciences — Technical Presentation (November 2023) on 6ix